







an Open Access Journal by MDPI

# **First-Line Therapy in Thoracic Oncology**

Guest Editors:

### Dr. Antonio D'Andrilli

Department of Thoracic Surgery, University of Messina, Via Consolare Valeria, 1-98124 Messina, Italy

#### Dr. Giulio Maurizi

Department of Thoracic Surgery, Sant'Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189 Rome, Italy

Deadline for manuscript submissions:

31 October 2024

# **Message from the Guest Editors**

Dear Colleagues,

Thoracic neoplasms include a heterogeneous group of diseases requiring multidisciplinary interaction for diagnosis and treatment. Lung cancer is surely the leading cause of cancer-related deaths worldwide. Over the last decades, significant advancements have been achieved in managing these tumors, especially when considering diagnostic tools for staging and restaging, integrated oncological protocols and refinements in surgical technique. Progresses in surgical approach have included minimally invasive procedures and increasing experience with more extended reconstructive operations.

The aim of this Special Issue, "First-Line Therapy in Thoracic Oncology" will focus on some of the main diagnostic and therapeutic aspects in thoracic oncology, to highlight topics from the perspective of different specialties involved in this field.

We invite you to contribute with an original article or a review article dealing with a topic in the research area of Thoracic Oncology. Let us know if you are interested providing a title for your contribution.

We look forward to receiving your contributions.













an Open Access Journal by MDPI

### **Editor-in-Chief**

### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**